DPYSL2 and early-onset autosomal dominant Alzheimer disease: Along these lines, a recent study reported the small molecule edonerpic maleate (T-817MA, 1 -{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol maleate), a candidate therapeutic for Alzheimer’s disease found to increase neurite outgrowth [9], as a novel CRMP2-binding compound with the potential to decrease its phosphorylation level in cortical tissues in vivo [10].